MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.semarthrit.2024.152482

Медицинская библиотека · Seminars in arthritis and rheumatism · 2024

The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.

Liew Jean W, Treu Timothy, Park Yojin, Ferguson Jacqueline M, Rosser Morgan A, Ho Yuk-Lam, Gagnon David R, Stovall Rachael, Monach Paul, Heckbert Susan R, Gensler Lianne S, Liao Katherine P, Dubreuil Maureen

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Whether tumor necrosis factor inhibitor (TNFi) use is cardioprotective among individuals with radiographic axial spondyloarthritis (r-axSpA), who have heightened cardiovascular (CV) risk, is unclear. We tested the association of TNFi use with incident CV outcomes in r-axSpA.

METHODS

We identified a r-axSpA cohort within a Veterans Affairs database between 2002 and 2019 using novel phenotyping methods and secondarily using ICD codes. TNFi use was assessed as a time-varying exposure using pharmacy dispense records. The primary outcome was incident CV disease identified using ICD codes for coronary artery disease, myocardial infarction or stroke. We fit Cox models with inverse probability weights to estimate the risk of each outcome with TNFi use versus non-use. Analyses were performed in the overall cohort, and separately in two periods (2002-2010, 2011-2019) to account for secular trends.

RESULTS

Using phenotyping we identified 26,928 individuals with an r-axSpA diagnosis (mean age 63.4 years, 94 % male); at baseline 3633 were TNFi users and 23,295 were non-users. During follow-up of a mean 3.3 ± 4.2 years, 674 (18.6 %) TNFi users had incident CVD versus 11,838 (50.8 %) non-users. In adjusted analyses, TNFi use versus non-use was associated with lower risk of incident CVD (HR 0.34, 95 % CI 0.29-0.40) in the cohort overall, and in the two time periods separately.

CONCLUSION

In this r-axSpA cohort identified using phenotyping methods, TNFi use versus non-use had a lower risk of incident CVD. These findings provide reassurance regarding the CV safety of TNFi agents for r-axSpA treatment. Replication of these results in other cohorts is needed.

Для цитирования: Liew Jean W, Treu Timothy, Park Yojin, Ferguson Jacqueline M, Rosser Morgan A, Ho Yuk-Lam, Gagnon David R, Stovall Rachael, Monach Paul, Heckbert Susan R, Gensler Lianne S, Liao Katherine P, Dubreuil Maureen. The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.. Seminars in arthritis and rheumatism. 2024. DOI: 10.1016/j.semarthrit.2024.152482.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.